PHARMAC  is consulting on proposed changes to the NIS affecting: 

• Pneumococcal conjugated (PCV13) vaccine;
• Varicella vaccine; Haemophilus influenzae type B (Hib) vaccine; 
• transition period for Brand switches and introduction of  Pneumococcal (PCV10) vaccine (Synflorix), Measles, mumps and rubella vaccine (Priorix),  Haemophilus influenzae type B vaccine (Hiberix); and Rotavirus vaccine (Rotarix);
• Minor clarifications to special authority criteria for Hepatitis B recombinant vaccine and Pneumococcal (PPV23) polysaccharide vaccine; and
• Tuberculin purified protein derivative (Mantoux) test

Feedback due: Please send feedback to [email protected]  by 13 January 2017.